Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02895906
Other study ID # MDGN-NFC1-22Q-101
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date November 28, 2016
Est. completion date April 20, 2017

Study information

Verified date March 2022
Source Cerecor Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a 5-week, multi-center, open-label, dose optimization trial in subjects aged 12-17 years with 22q11DS who have a diagnosis of anxiety disorder, and/or ADHD, and/or ASD. Approximately 12 subjects will be initiated, dose optimized, and maintained on NFC-1 over a period of 5 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 2
Est. completion date April 20, 2017
Est. primary completion date April 13, 2017
Accepts healthy volunteers No
Gender All
Age group 12 Years to 17 Years
Eligibility Inclusion Criteria: - Subject has a diagnosis of a 22q11.2 deletion prior to screening. - Subject has a diagnosis of anxiety disorder and/or ADHD and/or ASD based upon diagnostic evaluations performed at screening, history, and clinical judgement. - Subject is judged to be in general good health, other than having anxiety disorder and/or ADHD and/or ASD and 22q11DS. Medical conditions related to 22q11DS must be clinically stable post surgical correction and/or medical management. - Subject has no clinically significant abnormality on 12-lead electrocardiogram (ECG) performed at screening or baseline such as serious arrhythmia, bradycardia, tachycardia, cardiac conduction problems, or other abnormalities deemed to be a potential safety issue. - Subject and parent/legal guardian understand the study procedures and agree to the subject's participation in the study as indicated by parental/legal guardian signature on the subject informed consent form and subject's signature on the assent form. Exclusion Criteria: - Subject has a diagnosis of co-morbid major psychiatric disorders (ie, aside from anxiety disorder, ADHD, and/or ASD), including major depression, bipolar disease, schizophrenia (or any psychotic disorder), and moderate or severe intellectual disability, which in the opinion of the investigator may interfere with the conduct of study evaluations. - Subject has an IQ < 65 as determined by the Wechsler Abbreviated Scale of Intelligence. - Subject has a history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the subject by his/her participation in the study. - Subject has a history of clinically significant endocrine, gastrointestinal, cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or disease which is not currently stable clinically. Subjects with a history of uncomplicated kidney stones may be enrolled in the study at the discretion of the investigator. - Subject has a history of stroke, chronic seizures, or other major neurological disorder which, in the opinion of the investigator, would interfere with the subject's ability to participate and/or be evaluated in the trial. - Subject is currently considered at risk for suicide (in the opinion of the investigator), has previously made a suicide attempt, or is currently demonstrating active suicidal ideation. - Subject has taken any antidepressants, antipsychotics, anxiolytics, or non-stimulant ADHD medication within 30 days of the Screening Visit. - Subject is taking a prohibited medication

Study Design


Intervention

Drug:
NFC-1
Doses of NFC-1 will be administered as 50, 100, 200, or 400 mg twice daily as size 2, hard gelatin capsules for oral administration.

Locations

Country Name City State
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Aevi Genomic Medicine, LLC, a Cerecor company

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Time to symptom relapse Through study completion, up to 5 weeks
Secondary Response to treatment based on Clinical Global Impression - Improvement scale Through study completion, up to 5 weeks
Secondary Safety and tolerability as determined by AEs, laboratory results, C-SSRS, and K-SADS Through study completion, up to 5 weeks
See also
  Status Clinical Trial Phase
Terminated NCT04639960 - Neuroprotective Effects of Risperdal on Brain and Cognition in 22q11 Deletion Syndrome N/A
Recruiting NCT04373226 - Arithmetic Abilities in Children With 22q11.2DS N/A
Completed NCT01781923 - Cognitive Remediation in 22q11DS N/A
Terminated NCT03284060 - Social Cognition Training and Cognitive Remediation N/A
Recruiting NCT04639388 - Understanding of Psychotic Disorders in Children With 22q11.2DS N/A
Completed NCT00916955 - Genetic Modifiers for 22q11.2 Syndrome
Recruiting NCT05924347 - Early Scoliotic Changes in Children at Increased Risk for Scoliosis Development
Recruiting NCT00556530 - Examining Genetic Factors That Affect the Severity of 22q11.2 Deletion Syndrome
Completed NCT02460328 - Resolution of Primary Immune Defect in 22q11.2 Deletion Syndrome N/A
Completed NCT04647500 - Effects of Methylphenidate on Brain and Cognition in 22q11 Deletion Syndrome N/A